Synthesis, development and in vitro evaluation of drug delivery systems with protective effect against degradation by pepsin

被引:16
作者
Bernkop-Schnürch, A
Kirchmayer, R
Kratzel, M
机构
[1] Univ Vienna, Ctr Pharm, Inst Pharmaceut Technol, A-1090 Vienna, Austria
[2] Univ Vienna, Inst Pharmaceut Chem, A-1090 Vienna, Austria
关键词
drug delivery system; pepsin; pepsin inhibitor; pepstatin analogue; peroral administration of (poly)peptides;
D O I
10.3109/10611869909085492
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A (poly)peptide drug delivery system providing a protective effect against degradation by pepsin has been generated. A simplified pepstatin analogue was thereby synthesised displaying a terminally located primary amino group allowing an easy covalent attachment to anionogenic mucoadhesive polymers by the formation of amide bonds. The IC50 of this novel inhibitor was determined to be 6.65 +/- 1.05 x 10(-6) M. Mediated by a carbodiimide it was covalently bound to polycarbophil and sodium carboxymethyl cellulose (NaCMC). In contrast to polycarbophil-inhibitor conjugates, NaCMC-inhibitor conjugates displayed a high inhibitory effect towards pepsin. The protective effect of tablets containing a NaCMC-pepsin inhibitor conjugate (10%), NaCMC (56.7%), insulin(3.3%), and mannitol (30%) was evaluated in vitro. Tablets were therefore incubated for 2 h at 37 degrees C with simulated gastric fluid according to the Pharmacopoeia Europea. Following analysis demonstrated that 50.8 +/- 8.6% (mean +/- SD; n = 3) of insulin were degraded within the swollen carrier matrix, whereas insulin was completely metabolised in tablets without the NaCMC-pepsin inhibitor conjugate. This protective effect against degradation by pepsin might make such dosage forms useful tools for a targeted (poly)peptide delivery to the stomach.
引用
收藏
页码:55 / 63
页数:9
相关论文
共 19 条
[1]   The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins [J].
Bernkop-Schnurch, A .
JOURNAL OF CONTROLLED RELEASE, 1998, 52 (1-2) :1-16
[2]   Basic studies on bioadhesive delivery systems for peptide and protein drugs [J].
Bernkop-Schnürch, A ;
Humenberger, C ;
Valenta, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 165 (02) :217-225
[3]  
Bernkop-Schnürch A, 1999, STP PHARMA SCI, V9, P83
[4]   Novel bioadhesive drug delivery system protecting (poly)peptides from gastric enzymatic degradation [J].
BernkopSchnurch, A ;
Dundalek, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 138 (01) :75-83
[5]   Recombinant human transforming growth factor beta 3 accelerates gastric ulcer healing in rats [J].
Coerper, S ;
Sigloch, E ;
Cox, D ;
Starlinger, M ;
Koveker, G ;
Becker, HD .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (10) :985-990
[6]   PROTECTION OF GASTRIC-MUCOSA AGAINST ETHANOL-INDUCED INJURY BY INTRAGASTRIC BOLUS ADMINISTRATION OF EPIDERMAL GROWTH-FACTOR COMBINED WITH HYDROXYPROPYLCELLULOSE [J].
ITOH, M ;
IMAI, S ;
JOH, T ;
KAWAI, T ;
KATSUMI, K ;
YOKOCHI, K ;
TAKEUCHI, T .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1992, 14 :S127-S130
[7]   GASTRIC-ULCER TREATMENT WITH INTRAVENOUS HUMAN EPIDERMAL GROWTH-FACTOR - A DOUBLE-BLIND CONTROLLED CLINICAL-STUDY [J].
ITOH, M ;
MATSUO, Y .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1994, 9 :S78-S83
[8]   Effect of intragastric administration of beta-endorphin on thyrotropin-releasing hormone and somatostatin release into gastric lumen of rats [J].
Konagaya, T ;
Kusugami, K ;
Yamamoto, H ;
Nishio, Y ;
Kaneko, H ;
Nagai, H ;
Mitsuma, T .
JOURNAL OF GASTROENTEROLOGY, 1998, 33 (01) :27-31
[9]   Auxiliary agents for the peroral administration of peptide and protein drugs:: Synthesis and evaluation of novel pepstatin analogues [J].
Kratzel, M ;
Hiessböck, R ;
Bernkop-Schnürch, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (13) :2339-2344
[10]   ORAL ABSORPTION OF PEPTIDES - THE EFFECT OF ABSORPTION SITE AND ENZYME-INHIBITION ON THE SYSTEMIC AVAILABILITY OF METKEPHAMID [J].
LANGGUTH, P ;
MERKLE, HP ;
AMIDON, GL .
PHARMACEUTICAL RESEARCH, 1994, 11 (04) :528-535